Opportunity BasketBBB Crossing Peptide Library & Screening Service
A specialized contract research service that screens and optimizes drug candidates for BBB permeability using a proprietary library of known BBB-crossing peptide sequences and conjugation chemistry. Pharma companies submit their lead compounds; the service rapidly tests them against the library, identifies optimal peptide conjugates, and delivers validated BBB-crossing variants within 8-12 weeks—eliminating the need for $125M+ platform acquisitions.
32 weeks • 70% confidence
Value Proposition
Reduces BBB delivery problem-solving from 18-24 months and $125M+ acquisition cost to 8-12 weeks and $2-5M per compound, allowing pharma to test BBB feasibility before committing to platform licensing. Transfers technical risk away from pharma's internal teams onto specialized experts.
Target Audience
Mid-to-large pharma companies (Roche, Eli Lilly, Biogen, Regeneron) with neuroscience pipelines stalled at BBB delivery; biotech firms with 1-3 lead CNS candidates seeking faster, cheaper validation before full platform investment.
Key Features
- Proprietary library of 500+ validated BBB-crossing peptide scaffolds with published PK/BBB penetration data
- High-throughput conjugation chemistry (solid-phase synthesis automation) to generate 50-100 variants per compound per week
- In vitro BBB permeability screening (MDCK-MDR cells, hCMEC/D3 monolayers) with quantified penetration metrics
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Pharmaceutical companies cannot effectively deliver drugs across the blood-brain barrier to treat neurological diseasesPharma companies struggle to transport therapeutic drugs across the blood-brain barrier (BBB), a critical biological obstacle that blocks most drug molecules from reaching the brain and central nervous system. This failure results in abandoned neuroscience pipelines, failed clinical trials, and inability to treat neurological disorders like Alzheimer's, Parkinson's, and brain tumors. Current delivery methods are ineffective, forcing companies to acquire specialized platform technologies at premium prices ($125M+) just to solve this single technical bottleneck.
Score: 49.6% • 1 payment signal